In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shire/TKT: The Price of Diversification

Executive Summary

Shire's proposed $1.6 billion cash takeover of TKT answers investors' call for some deal-making action and pipeline diversification. But critics say Shire has paid over the odds for some risky programs in unfamiliar territory--rather like it did with BioChem.
Advertisement

Related Content

Cydan Hopes To Accelerate Rare Disease Drug Development With $16M Raise
Shire Adds To HGT Unit With Lotus Acquisition; Gets Preclinical Rare Disease Treatment
Shire Nabs Advanced BioHealing Just Prior To Planned IPO
Shire: Remodeling Specialty Pharma
Cephalon: Can Spec Pharma do R&D?
Kos/Biovail: How a Mid-Cap Can Win in Primary Care
Shire: Proving the Specialty Model
Shire: Proving the Specialty Model
Shire Shifts Upstream
Shire Shifts Upstream

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002572

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel